Results 121 to 130 of about 320,703 (320)

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

Canadian Journal of Gastroenterology and Hepatology, 2014
Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEG-IFN) and ribavirin (RBV).
A. Yau, E. Yoshida
semanticscholar   +1 more source

Virtual screening for NS5B inhibitors of Hepatitis C virus [PDF]

, 2012
Hepatitis C Virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at a risk of developing significant morbidity and mortality.
Achuthsankar S. Nair, Amjesh R, Sugunan V.S.   +2 more
core   +2 more sources

Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review

Brazilian Journal of Infectious Diseases, 2014
Pegylated interferon alpha (Peg IFN-α) in combination with ribavirin is the backbone of treatment in chronic hepatitis C (CHC). Cardiotoxicity due to interferon therapy is rare.
Wenxue Zhao, Fanpu Ji, Shanshan Yu, Zongfang Li, Hong Deng   +4 more
doaj   +1 more source

Short‐ and long‐term effects of therapy with interferon‐α and pegylated interferon‐α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C [PDF]

, 2004
Monika Homoncik, Arnulf Ferlitsch, Péter Ferenci, Elisabeth Formann, Bernd Jilma, Alfred Gangl, Simon Panzer, Markus Peck‐Radosavljevic   +7 more
openalex   +1 more source

Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)

RUDN Journal of Medicine, 2014
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin.
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya   +7 more
doaj  

Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient

Clinics and Practice, 2011
Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory ...
Emanuele Durante-Mangoni, Domenico Iossa, Umberto Malgeri   +2 more
doaj   +1 more source

Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report [PDF]

, 2009
Özlen Atuğ, Hakan Akın, Yeşim Özen Alahdab, Berrin Ceyhan, Nurdan Tözün, Osman Özdoğan   +5 more
openalex   +1 more source

Test system for the detection of binding antibodies to interferon beta-1a for clinical use

Биопрепараты: Профилактика, диагностика, лечение, 2018
Test system for determining the presence of binding antibodies to interferon beta-1a (BAB to IFN beta-1a) in serum using ELISA has been developed.
E. A. Kuzminova, T. Yu. Ostroukhova, A. V. Grachev, E. L. Morozova   +3 more
doaj  

Hepatitis C Screening in the Homeless Population of Philadelphia [PDF]

, 2016
Hepatitis C is a viral infectious disease that is a major cause of liver disease around the world. By the 1970s, it was recognized that many hepatitis cases were not due to the known hepatitis A or hepatitis B viruses.
Zimilover, Adam
core   +1 more source

Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin [PDF]

, 2008
Jeffrey J. Weiss, Laveeza Bhatti, Douglas T. Dieterich, Brian R. Edlin, Dawn Fishbein, Matthew Bidwell Goetz, Kenneth H. Yu, Glenn J. Wagner   +7 more
openalex   +1 more source